共 109 条
[1]
Paez JG(2004)EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 1497-1500
[2]
Jänne PA(2004)Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2129-2139
[3]
Lee JC(2005)High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib Cancer 103 2344-2348
[4]
Tracy S(2010)Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer Cancer 116 1336-1343
[5]
Greulich H(2006)Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib J Clin Oncol 24 4517-4520
[6]
Gabriel S(2009)Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib J Thorac Oncol 4 1415-1419
[7]
Herman P(2009)Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib J Clin Oncol 27 31-32
[8]
Kaye FJ(2010)High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer J Neurooncol 99 283-286
[9]
Lindeman N(2011)High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer J Thorac Oncol 6 653-654
[10]
Boggon TJ(2010)Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer J Thorac Oncol 5 950-955